Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays
- PMID: 15528715
- PMCID: PMC525161
- DOI: 10.1128/JCM.42.11.5199-5204.2004
Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays
Abstract
Recent clinical studies suggest that hepatitis B virus (HBV) load and genotype may be independent predictors of responses to antiviral therapies. However, it is difficult for clinicians to accurately determine viral loads in patient samples because results--both the values and the units of measure--can vary greatly among different tests. Accordingly, the World Health Organization (WHO) has produced the first international standard for HBV DNA for nucleic acid amplification technology (NAT) assays. In the present study, we describe the performance of the target-capture PCR HBV DNA quantitative assay for the quantitation of HBV DNA in clinical samples and reference panels. The range of quantitation was between 50 and 10(10) IU/ml. The sensitivity and accuracy of the target-capture PCR assay were demonstrated by using the HBV panel from Quality Control for Medical Diagnostics (QCMD) and the WHO HBV DNA standard. The target-capture PCR assay quantitated the six genotype A members of the QCMD panel and dilutions of the WHO HBV DNA standard within an accuracy of 74 to 142%. Compared to current serological methods, the assay offers window period reductions of 19 days prior to HBV surface antigen and 26 days prior to HBV e antigen detection. The target-capture PCR assay was also compared with four commercially available NAT assays, and the various units of measure were standardized with respect to the international units of the WHO HBV DNA standard. The target-capture PCR assay is a sensitive, accurate, high-throughput, rapid, and reproducible assay for the determination of HBV loads.
Similar articles
-
Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.J Clin Microbiol. 2006 Apr;44(4):1390-9. doi: 10.1128/JCM.44.4.1390-1399.2006. J Clin Microbiol. 2006. PMID: 16597867 Free PMC article.
-
Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes.J Virol Methods. 2006 Jul;135(1):83-90. doi: 10.1016/j.jviromet.2006.02.004. Epub 2006 Mar 23. J Virol Methods. 2006. PMID: 16551481
-
Real-time PCR quantitation of hepatitis B virus DNA using automated sample preparation and murine cytomegalovirus internal control.J Virol Methods. 2005 Jun;126(1-2):207-13. doi: 10.1016/j.jviromet.2005.03.001. J Virol Methods. 2005. PMID: 15847939
-
Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products.J Clin Virol. 2001 Jan;20(1-2):7-13. doi: 10.1016/s1386-6532(00)00149-9. J Clin Virol. 2001. PMID: 11163577 Review.
-
The potential advantages of digital PCR for clinical virology diagnostics.Expert Rev Mol Diagn. 2014 May;14(4):501-7. doi: 10.1586/14737159.2014.910456. Epub 2014 Apr 11. Expert Rev Mol Diagn. 2014. PMID: 24724628 Review.
Cited by
-
Detection and monitoring of virus infections by real-time PCR.Mol Aspects Med. 2006 Apr-Jun;27(2-3):254-98. doi: 10.1016/j.mam.2005.12.001. Epub 2006 Feb 14. Mol Aspects Med. 2006. PMID: 16481036 Free PMC article. Review.
-
Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.J Clin Microbiol. 2006 Apr;44(4):1390-9. doi: 10.1128/JCM.44.4.1390-1399.2006. J Clin Microbiol. 2006. PMID: 16597867 Free PMC article.
-
Evaluation of Chronic Hepatitis B Infection in Patients with Seronegative HbsAg.Iran J Public Health. 2012;41(2):100-4. Epub 2012 Feb 29. Iran J Public Health. 2012. PMID: 23113141 Free PMC article.
-
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.J Viral Hepat. 2014 Apr;21(4):288-96. doi: 10.1111/jvh.12142. Epub 2013 Jul 30. J Viral Hepat. 2014. PMID: 24597697 Free PMC article.
-
Comparison of Abbott and Da-an real-time PCR for quantitating serum HBV DNA.World J Gastroenterol. 2014 Sep 7;20(33):11762-9. doi: 10.3748/wjg.v20.i33.11762. World J Gastroenterol. 2014. PMID: 25206280 Free PMC article.
References
-
- Benjamin, R. J. 2001. Nucleic acid testing: update and applications. Semin. Hematol. 38:11-16. - PubMed
-
- Berger, A., W. Preiser, and H. W. Doerr. 2001. The role of viral load determination for the management of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infection. J. Clin. Virol. 20:23-30. - PubMed
-
- Biswas, R., E. Tabor, C. C. Hsia, D. J. Wright, M. E. Laycock, E. W. Fiebig, L. Peddada, R. Smith, G. B. Schreiber, J. S. Epstein, G. J. Nemo, and M. P. Busch. 2003. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 43:788-798. - PubMed
-
- Busch, M. P., and S. H. Kleinman. 2000. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. Transfusion 40:143-159. - PubMed
-
- Grant, P. R., and M. P. Busch. 2002. Nucleic acid amplification technology methods used in blood donor screening. Transfusion Med. 12:229-242. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical